Hospital stay was slightly different in that the average length of stay was the digami study. Importantly, the varying glucose target levels of these studies make it difficult to compare their results and infer a firm conclusion. This study aimed to examine the effect of a diabetes payforperformance p4p program on allcause mortality in patients with newly diagnosed type 2 diabetes mellitus. The fds2 is a prospective communitybased study of 1668 people with diabetes. Before randomization, the patients were stratified into 4 groups on the basis of risk. Intense metabolic control by means of insulin in patients. Hyperglycemia at the time of hospital admission predicts increased mortality in patients with acute coronary syndromes acs, including stsegment elevation myocardial infarction stemi. Diabetes mellitus, insulinglucose infusion in acute. Publications home of jama and the specialty journals of.
Context glucoseinsulinpotassium gik infusion is a widely applicable, lowcost therapy that has been postulated to improve mortality in patients with acute stsegment elevation myocardial infarction. The effects of insulin on the endothelium sciencedirect. Diabetes payforperformance program can reduce allcause. Opie lmetabolism of free fatty acids, glucose and catecholamines in acute. In diabetics who have had an mi, the digami study showed that intravenous insulin for 24 hours and subcutaneous insulin for 3 months improved mortality rates for up to 3 years after. Hyperglycemia and adverse outcomes in acute coronary. In the first digami study, an insulinbased glucose management. Effect of insulinglucose infusion on mortality following. The digami study underscores the importance of early and aggressive interventions designed to bring glucose levels into the normal range regardless of a patients prior diabetes status. The first study using this strategy, diabetes and insulinglucose infusion in acute myocardial infarction digami, found that intensive insulin treatment in patients with type 2 diabetes and acute myocardial. The recent digami study demonstrated that the 1year prognosis in diabetic patients. Exclusion criteria were inability to cope with insulin treatment or to receive information on the study. Pdf selfrated health predicts outcome in patients with.
The digami 2 study was an international 48center trial involving 3000 subjects with a trial design similar to that of digami 1, enrolling persons with known diabetes or with initial glucose. You can manage this and all other alerts in my account. The digami 2 trial is soon to be completed, to address questions of the mechanism of benefit and whether acute or chronic glycemic treatment is of greater benefit, in a threearm study of persons with type 2 diabetes or initial glucose 11 mmoll, as well as ami, comparing the full digami regimen with only the acute insulin infusion. The digami study compared conventional antidiabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of mi and. Pdf fasttrack intense metabolic control by means of insulin in. The study conformed to good clinical practice guidelines and followed the recommendations of the helsinki declaration. Pdf patients with diabetes have an unfavourable prognosis after an.
For example, in the digami study, a striking increase was seen in longterm mortality in patients who had very high glucose concentrations on admission. This is probably explained by the fact that the baseline glucose control was considerably better than in digami 1 already at the onset of. Recent studies have indicated that not only glucose control as such, but also. It is well established that hyperglycaemia is common in patients admitted to the hospital with acute coronary syndrome acs, and is an an independent risk factor for adverse outcome. The digami study compared conventional antidiabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of mi and thricedaily subcutaneous insulin injection for the remainder of the hospital stay and a minimum of 3 months thereafter. The digami study on the use of intravenous insulin infusion atthe time of myocardial. Patients assigned to the intensive insulininfusion arm received standard insulin and dextrose. Malmberg k1, ryden l, efendic s, herlitz j, nicol p, waldenstrom a, wedel h, welin l.
Hyperglycemia and acute coronary syndrome circulation. Mar 04, 2019 metabolism of free fatty acids, glucose, and catacholamines in acute myocardial infarction. We used multivariate cox proportional hazard models analysis to investigate the effect of the p4p program and adherence on allcause mortality. The digami 2 diabetes mellitus insulin glucose infusion in acute myocardial. Jan 18, 2005 the digami 2 diabetes mellitus insulin glucose infusion in acute myocardial infarction 2 trial, recently presented at the european association for the study of diabetes meeting in munich, germany, has left many physicians disappointed, but there should be no grounds for despair. The diabetes insulinglucose in acute myocardial infarction digami trial demonstrated significant reductions in mortality when an intensive insulin regimen was administered to. Among the spectral domain measures, after adjustment for age, sex, baseline hrv measure, history of myocardial infarction, bmi at study exit, physical activity level at study exit, and. The digami study on the use of intravenous insulin infusion at the time of myocardial infarction mi has stimulated a large number of discussion papers on the best treatment of mi in the. Admission hyperglycemia and acute myocardial infarction. Variability of blood glucose concentration and shortterm. To explore if hypoglycaemic episodes during hospitalisation influence the subsequent prognosis in patients with diabetes and acute myocardial infarction. The digami study demonstrated that the unfavorable longterm prognosis could be improved by insulin treatment 4, extending. Selfrated health predicts outcome in patients with type 2 diabetes. The concept of initiating treatment with insulin infusion to rapidly attain.
Hyperglycaemia and myocardial infarction british journal of. Prognostic implications of glucoselowering treatment. The effects of insulin on the endothelium vivian a. On the basis of these findings, the diabetes mellitus insulin glucose infusion in acute myocardial infarction digami 1 trial was started. Why does this approach raise such a serious concern.
Diabetic cardiology pdf free pdf epub medical books. Metabolism of free fatty acids, glucose, and catacholamines in acute myocardial infarction. In diabetes, the postprandial phase is characterized by a rapid and. Nice recommendations for the management of hyperglycaemia in. The digami study compared conventional antidiabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of mi and thricedaily subcutaneous insulin injection for. Randomised trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute.
The digami study compared conventional antidiabetic therapy to intensive. Experience from the code study 18 and registries 19 does indeed. Among the spectral domain measures, after adjustment for age, sex, baseline hrv measure, history of myocardial infarction, bmi at study exit, physical activity level at study exit, and baseline depression and anger scores, there was a statistically significant difference in. Dec 14, 2007 the digami study on the use of intravenous insulin infusion at the time of myocardial infarction mi has stimulated a large number of discussion papers on the best treatment of mi in the diabetic patient. Variability of blood glucose concentration and shortterm mortality in critically ill patients. A detailed description of the digami study has been given elsewhere.
Prognostic implications of hypoglycaemic episodes during. Many presentations at the ada meeting addressed aspects of the relationship between diabetes and cardiovascular disease cvd. The recent digami study demonstrated that the 1year prognosis in diabetic. Retrospective data from two large scale studies, eur heart j, 10 1989, pp. Apr 21, 2019 the digami study compared conventional antidiabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of mi and. In the first digami study, an insulinbased glucose. The interpretation of digami 2 is that for a similar glycaemic control insulin treatment is not superior to the use of other therapeutic options as regards mortality. Selfrated health predicts outcome in patients with type 2 diabetes and myocardial infarction. Publications home of jama and the specialty journals of the. Fonseca, md, frcp professor of medicine and pharmacology, tullis tulane alumni chair in diabetes, chief, section of endocrinology, tulane. Karin bornfeldt seattle, wa described evidence from mouse models, suggesting that dyslipidemia. While the digami study was able to demonstrate a decrease in both mortality and mean 24hour blood glucose levels, the digami2 and hi5 studies showed no such significant decrease figure 2 2729. A detailed description of digami including study design, definitions and methods has been given elsewhere. A possible effect, common to both treatment modalities, is a reduction of free fatty.
Diabetes payforperformance program can reduce allcause mo. Variability of blood glucose concentration and shortterm mortality in critically ill patients you will receive an email whenever this article is corrected, updated, or cited in the literature. In the digami study, 620 patients with acute myocardial infarction and hyperglycemia with and without prior history of diabetes were randomized to either intravenous iv insulin. A report from the digami 2 trial european heart journal 2008. There might be several explanations for the lack of effects of gik in stemi. Jul, 2019 the nature of the study, a truly investigatorinitiated trial, rendered it a lowbudget trial despite generous research grants. In addition, an excessive oxidation of free fatty acids may possibly jeopardize. Overall, this study was successful in showing the feasibility and potential advantage of aggressive longterm insulin management in diabetic patients with mis. Intense metabolic control by means of insulin in patients with. Hyperglycaemia and myocardial infarction british journal. Hospital stay was slightly different in that the average length of stay was the digami study compared conventional antidiabetic therapy to intensive insulin therapy consisting of acute insulin infusion during the early hours of mi and thricedaily subcutaneous insulin injection for the remainder. Randomized trial of insulinglucose infusion followed by. The digami 2 diabetes mellitus insulin glucose infusion in acute myocardial infarction 2 trial, recently presented at the european association for the study of diabetes meeting in munich. Hyperglycemia at the time of hospital admission predicts increased mortality in patients with acute coronary syndromes acs, including stsegment elevation myocardial infarction stemi 16, revascularization procedures such as thrombolysis or percutaneous coronary intervention pci 710, and other critical illnesses 11.
Prognostic implications of glucoselowering treatment in patients. On the basis of a small study and the use of historical control subjects, clark et al. Stress hyperglycaemia and increased risk of death after. Prakash deedwania, mikhail kosiborod, eugene barrett, antonio ceriello, william isley, theodore mazzone, philip raskin. First, the overall mortality in digami 2 was lower than expected. Postprandial hyperglycemia and diabetes complications. Briefly, this is a multicentre, randomised, prospective study on the effect on mortality and morbidity of an intravenous infusion of insulinglucose followed by 4dose subcutaneous insulin therapy given to patients with suspected acute. The digami 2 study was an international 48center trial involving 3000. Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction.
The hi5 study attempted to rectify some of the issues that were encountered in digami 2. Within the framework of the clinical trial digami 2 hypoglycaemic episodes blood glucose study of 1668 people with diabetes. Pmc free article malmberg k, ryden l, efendic s, herlitz j, nicol p, waldenstrom a, wedel h, welin l. The 1 year mortality was reduced by 30% in the intensively treated group. Randomized trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic. The digami 2 trial is soon to be completed, to address questions of the mechanism of benefit and whether acute or chronic glycemic treatment is of greater benefit, in a threearm study of. Hospital management of diabetes college of medicine.
Digami 2, a prospective, randomised open trial with blinded. The digami study on the use of intravenous insulin infusion at the time of myocardial infarction mi has stimulated a large number of discussion papers on the best treatment of mi in the diabetic patient. Glucoseinsulinpotassium infusion in patients with acute. Mortality prediction in diabetic patients with myocardial. The relationship between blood glucose and mortality. Increasing evidence suggests that the postprandial state is a contributing factor to the development of atherosclerosis. Glucose and potassium derangements by glucoseinsulin. Digami 2disappointment but not despair mccallum 2004. The digami 2 diabetes mellitus insulin glucose infusion in acute myocardial infarction 2 trial, recently presented at the european association for the study of diabetes meeting in munich, germany, has left many physicians disappointed, but there should be no grounds for despair.
Betablockers, for example, reduce free fatty acid levels, a potential. Mortality prediction in diabetic patients with myocardial infarction. Randomized trial of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction digami study. Nice recommendations for the management of hyperglycaemia. The nature of the study, a truly investigatorinitiated trial, rendered it a lowbudget trial despite generous research grants. This is the sixth in a series of articles on presentations at the american diabetes association annual meeting, san diego, california, 1014 june 2005.
1457 545 715 1319 359 980 938 1268 232 585 105 670 1346 679 260 1160 663 120 267 55 715 639 572 1137 763 443 54 553 814 519 385 1004 1420 315 118 784 303